Who Owns Xcenda?

What does Cencora do?
Cencora distributes pharmaceutical products, including brand-name drugs, generic drugs, and specialty medications, to pharmacies, hospitals, physician offices, and other healthcare providers across the United States and internationally. The company also provides manufacturer services, patient support programs, specialty logistics, and veterinary pharmaceutical distribution through its subsidiaries.

Is Cencora publicly traded?
Yes, Cencora, Inc. trades on the New York Stock Exchange under ticker symbol COR. The company has no controlling shareholder, though Walgreens Boots Alliance holds approximately 15% of shares as the largest single investor.

What is Cencora's annual revenue?
In fiscal year 2024 (ended September 30, 2024), Cencora reported revenue of $294.0 billion, a 12.1% increase from the prior fiscal year. The company is one of the largest companies in the United States by revenue.

Why did AmerisourceBergen change its name to Cencora?
AmerisourceBergen changed its name to Cencora in August 2023 to reflect its evolution from a primarily domestic pharmaceutical distributor into a global healthcare solutions organization. The rebranding followed the 2021 acquisition of Alliance Healthcare, which significantly expanded the company's international operations, and was intended to signal the company's broader capabilities beyond traditional drug distribution.

Who is Cencora's CEO?
Robert P. Mauch became President and CEO of Cencora on October 1, 2024, succeeding Steven H. Collis, who had served as CEO since 2011. Collis transitioned to the role of Executive Chairman.

What is Cencora's role in the opioid settlement?
Cencora, along with McKesson and Cardinal Health, reached a $21 billion settlement with U.S. states and local governments in 2022 to resolve claims that the three distributors failed to adequately monitor suspicious opioid orders. Cencora's share of the settlement is approximately $6.1 billion, to be paid over 18 years.